Touchlight appoints Karen Fallen as CEO of Touchlight DNA Services
Drug Discovery Today
OCTOBER 19, 2020
Former Lonza President of Biologics Manufacturing joins to continue rapid expansion of DNA contract manufacturing; Touchlight’s synthetic dbDNA in high demand as starting material in the manufacture of advanced therapies such as mRNA vaccines and cell and gene therapies
Let's personalize your content